SLC22A12 and chronic kidney disease: In a cohort study of 874 patients with CKD who were newly prescribed urate-lowering drugs, an URAT1 inhibitor, benzbromarone, was associated with a 50%-lower risk of kidney outcomes compared to allopurinol33.